Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $7 from $6.25 and keeps a Buy rating on the shares following the company’s Q4 pre-release. While exact contribution was not disclosed, the firm says the quarter likely saw continued strong execution both domestically and outside-U.S.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
- Koru Medical reports preliminary Q4 revenue $10.9M, consensus $10.46M
- Koru Medical submits FreedomEDGE 510(k) premarket notification to the FDA
- Koru Medical price target raised to $8 from $6 at Lake Street
- Koru Medical price target raised to $6 from $5 at Canaccord
- Koru Medical names Eric Schiller CTO